Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results

Rhea-AI Summary

Delcath Systems, Inc. (DCTH) will host a conference call on March 31, 2021, at 8:00 AM Eastern Time to discuss its fourth quarter results for the period ended December 31, 2020. Participants can join by dialing in 5 to 10 minutes early. The company focuses on treating rare liver cancers using its investigational product, HEPZATO KIT, which is designed for high-dose chemotherapy delivery. While CE Marked in Europe as CHEMOSAT, it is not yet approved by the FDA for U.S. sales.

Positive

• HEPZATO KIT is designed to deliver high-dose chemotherapy effectively.
• CHEMOSAT is CE Marked and used in major medical centers in Europe.

Negative

• HEPZATO KIT has not received FDA approval for sale in the U.S.

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on March 31, 2021 at 8:00 AM Eastern Time to discuss results for its fourth quarter ended December 31, 2020.

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: March 31, 2021
Time: 8:00 AM Eastern Time 
Toll Free: 877-407-8035
International: 201-689-8035

The call will also be available over the Internet and accessible at: https://www.webcaster4.com/Webcast/Page/2475/40544

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara 
(646)-755-7412 
james@haydenir.com

 

FAQ

What are the key details of Delcath Systems' conference call on March 31, 2021?

Delcath Systems will discuss fourth quarter results for 2020 during a conference call on March 31, 2021, at 8:00 AM Eastern Time. Participants should dial in 5 to 10 minutes early.

What is the current status of HEPZATO KIT by Delcath Systems?

HEPZATO KIT is not yet approved by the FDA for sale in the U.S., although it is CE Marked and used under the name CHEMOSAT in Europe.

How is Delcath Systems' investigational product HEPZATO KIT administered?

HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and minimizing side effects.